Prasco Laboratories — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Prasco Laboratories is a privately-held, commercial-stage pharmaceutical company based in Cincinnati, Ohio, and a recognized leader in the Authorized Generics (AG) market. The company's core business model is providing commercialization services and partnership solutions to brand-name pharmaceutical companies, enabling them to launch AG versions of their products, which are identical to the brand but sold at generic prices. With a history of launching more AGs than any other independent generics company, Prasco has established itself as a trusted partner through its 'Unlimit' strategy, focused on creating innovative market solutions. The company has facilitated significant cost savings for the healthcare system while maintaining a corporate culture built on its founding principles.

Generic Drugs

Technology Platform

Specialized commercialization and lifecycle management platform for Authorized Generics, centered on its 'Unlimit®' strategy of providing strategic partnership, regulatory, supply chain, and distribution services.

Opportunities

The ongoing patent expiry cliff for brand-name drugs and payer pressure for lower-cost alternatives creates a steady stream of opportunities for Authorized Generics.

Prasco can expand by becoming the preferred partner for more of the 60+ companies it works with and by extending its service model into adjacent areas of pharmaceutical commercialization and specialty distribution.

Risk Factors

High dependency on partnerships with brand pharmaceutical companies; vulnerability to aggressive pricing competition from traditional generics manufacturers; potential regulatory changes affecting the Authorized Generic pathway; and concentration risk if a major partner terminates an agreement.

Competitive Landscape

Prasco competes with the internal generic divisions of large pharmaceutical companies and other third-party commercialization firms. Its differentiation is its pure-play focus on Authorized Generics, its independent status which avoids channel conflict, and its reputation for best-in-class service and execution, having launched more AGs than any other independent company.

More companies in Small Molecule Drugs →More companies in United States →